ProPhase Precision Medicine

ProPhase Precision Medicine is the genomics and precision diagnostics subsidiary of ProPhase Labs. The company was formed in 2021 to build a business around whole genome sequencing, genomic testing, and related precision medicine services, and it later completed the acquisition of Nebula Genomics to expand those capabilities. Its offerings are centered on commercial whole genome sequencing and consumer- and research-oriented genomic services rather than a traditional therapeutic drug pipeline. The business has also been positioned by its parent as a source of genomic data, precision oncology insights, and potential AI-enabled applications in healthcare. Overall, ProPhase Precision Medicine appears to function primarily as a commercial genomics and diagnostics platform within the broader ProPhase Labs portfolio.